Sign in

Deborah C. Jackson

Lead Independent Director at Eastern Bankshares
Board

About Deborah C. Jackson

Deborah C. Jackson, age 73, is Lead Independent Director of Eastern Bank and has served on the board since 2000 (trustee of predecessor since 2001). She was President of Cambridge College from 2011 through December 2023 and previously CEO of the American Red Cross of Eastern Massachusetts and Vice President at The Boston Foundation; she holds a B.A. from Northeastern University, studied graduate urban studies/planning at MIT, and has honorary doctorates from Curry College and Merrimack Valley College . She has served as Lead Director since January 2018 with responsibilities including agenda-setting with the Chair, presiding over executive sessions, and coordinating independent director meetings .

Past Roles

OrganizationRoleTenureCommittees/Impact
Cambridge CollegePresident2011–Dec 2023Led institution; governance and executive leadership
American Red Cross of Eastern MassachusettsChief Executive Officer~10 years (prior to Cambridge College)Oversight of one of largest Red Cross units
The Boston FoundationVice PresidentPrior to Red CrossManaged $50M grant and initiatives program
Boston Stock ExchangeDirector; Audit Committee ChairPrior serviceChaired Audit Committee; market oversight

External Roles

OrganizationRoleTenureNotes
Amwell CorporationDirectorSince Oct 2020Public digital health company board service
John Hancock InvestmentsDirectorCurrentMutual fund complex governance
Eastern Bank FoundationTrusteeCurrentOversees foundation aligned with Company

Board Governance

  • Independence: Determined independent under Nasdaq rules; meets enhanced standards for committee service .
  • Lead Independent Director: Serves since Jan 2018; functions include agenda consultation, executive session leadership, and independent director coordination .
  • Committee assignments: Member, Compensation and Human Capital Management Committee (CHCM) ; Member, Nominating and Governance Committee .
  • Attendance: Board met 15 times in 2024 (8 regular, 7 special); each director attended over 75% of Board and committee meetings; all directors attended the 2024 annual meeting .
  • Declassification and refreshment: Board moving to annual elections by 2027; director retirement policy at age 75 .

Fixed Compensation

ComponentAmount ($)Detail
Board/Committee Cash Fees (Fees Earned)134,750Includes annual board retainer ($55,000), committee member fees ($5,000–$10,000), Lead Director retainer ($40,000), and meeting fees as applicable .
All Other Compensation17,160Accrued dividends paid on vesting of director restricted stock awards; plus matching charitable gifts (program cap $1,000 per director) .

Performance Compensation

Equity VehicleGrant Value ($)Grant DateVesting/Metrics
Restricted Stock (director annual grant)64,993May 13, 2024Time-based restricted stock granted annually; director awards do not use PSU metrics; dividends paid upon vesting of prior awards .

No director performance share units or option awards are disclosed; director equity consists of time-based restricted stock with annual grants roughly equal to $65,000 .

Other Directorships & Interlocks

  • Current public-company directorship: Amwell Corporation (since October 2020) .
  • Compensation committee interlocks: None—no officers served on EBC’s CHCM Committee; EBC executives did not serve on compensation committees of entities with reciprocal executive relationships .
  • Related party transactions: Company reports no disclosable related party transactions since the start of fiscal 2024; director/related-party loans were ordinary course on market terms without unfavorable features .

Expertise & Qualifications

  • Executive and civic leadership in higher education, healthcare, and philanthropy; prior audit committee chair experience (Boston Stock Exchange) .
  • Board governance leadership as Lead Director with defined responsibilities enhancing independent oversight .
  • Education and recognition: Northeastern B.A.; graduate studies at MIT; honorary doctorates; fellowships (Harvard Advanced Leadership Institute; Harvard Institute for College Presidents; British American Project) .

Equity Ownership

MeasureSharesNotes
Total Beneficial Ownership86,284As of March 14, 2025; <1% of outstanding shares .
Directly Held37,749Common stock held directly .
IRA19,000Shares held in an IRA .
Restricted Stock (subject to vesting)29,535Unvested restricted stock .
Ownership GuidelinesFive times cash retainerDirector stock ownership guidelines; compliance evaluated annually .
Compliance StatusMet or on trackAs of Jan 1, 2025, all non-employee directors met or were on track .
Hedging/PledgingProhibitedInsider Trading Policy bans hedging/pledging by directors .

Governance Assessment

  • Strengths:

    • Independent Lead Director with clear responsibilities enhances board effectiveness and independent oversight .
    • Active service on CHCM and Nominating committees supports pay governance, succession, and board refreshment; CHCM uses independent consultant (Pearl Meyer) and conducts annual risk assessments; no tax gross-ups; double-trigger CIC only—shareholder-friendly features .
    • Attendance and engagement strong; board/committee activity robust in 2024; all directors attended the 2024 annual meeting .
    • Director equity ownership guidelines and anti-hedging/pledging policy reinforce alignment; Jackson has meaningful share ownership .
  • Potential watch items:

    • Retirement policy at 75 implies expected board turnover in coming years; continued succession planning required .
    • Ordinary-course lending relationships to directors exist given bank status, but reported on market terms and not disclosable under RPT standards for 2024 .
  • Shareholder signals:

    • Say-on-pay support of 85.5% in 2024 indicates investor alignment with compensation oversight; relevant to her CHCM role .
    • Board moving to annual elections by 2027 enhances accountability; sustained role as Lead Director supports transition .